AV Secures $46.6M Contract with Italian Ministry of Defence for Combat-Proven JUMP 20 VTOL Aircraft System
ARLINGTON, Va.--(BUSINESS WIRE)--AeroVironment (AV), a global leader in intelligent, multi-domain autonomous systems, today announced it has been awarded a $46.6M contract by the Italian Ministry of Defence (MOD) for the delivery of its JUMP® 20 vertical takeoff and landing (VTOL) medium uncrewed aircraft system (MUAS). The five-year contract encompasses the procurement of JUMP 20 air vehicles, engineering services, initial sustainment and onsite technical support – ensuring rapid fielding and operational readiness from day one.
'This contract builds on our history of supporting NATO allies with world-class uncrewed systems that reflects our unwavering commitment to innovation and mission success reinforcing our reputation as a trusted partner our customers can rely on.'
Share
JUMP 20 is a vertical take-off and landing (VTOL), fixed-wing UAS with 30 pounds of payload capacity, 13+ hours of endurance and an operational range of 185 km (115 mi). Purpose-built for expeditionary operations, the system can be stored and transported with ease and autonomously launched and recovered without personnel intervention, making it ideal for dynamic on-the-move operations.
The selection follows a rigorous and highly competitive procurement process, where JUMP 20 distinguished itself for its ability to meet the Italian MOD's stringent technical and operational requirements while replacing their existing Shadow UAS fleet with a modern, adaptable solution.
'We are honored to strengthen our partnership with the Italian Ministry of Defence through the delivery of the JUMP 20, a system that enhances their operational capabilities,' said Shane Hastings, AV's vice president and general manager of Medium UAS. 'This contract builds on our history of supporting NATO allies with world-class uncrewed systems that reflects our unwavering commitment to innovation and mission success reinforcing our reputation as a trusted partner our customers can rely on.'
The JUMP 20 delivers advanced intelligence, surveillance, and reconnaissance (ISR) capabilities with multi-payload flexibility and seamless interoperability across current and future systems. Built on a Modular Open Systems Approach (MOSA), the platform enables rapid integration, easy upgrades, and unmatched adaptability to support a wide range of evolving mission demands.
ABOUT AEROVIRONMENT
AeroVironment (NASDAQ: AVAV) is a global leader in intelligent multi-domain robotic systems, uncrewed aircraft and ground systems, sensors, software analytics and connectivity. Headquartered in Arlington, Virginia, AeroVironment delivers actionable intelligence so our customers can proceed with certainty. For more information, visit www.avinc.com.
SAFE HARBOR STATEMENT
Certain statements in this press release may constitute "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are made on the basis of current expectations, forecasts and assumptions that involve risks and uncertainties, including, but not limited to, economic, competitive, governmental and technological factors outside of our control, that may cause our business, strategy or actual results to differ materially from those expressed or implied. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, our ability to perform under existing contracts and obtain additional contracts; changes in the regulatory environment; the activities of competitors; failure of the markets in which we operate to grow; failure to expand into new markets; failure to develop new products or integrate new technology with current products; and general economic and business conditions in the United States and elsewhere in the world. For a further list and description of such risks and uncertainties, see the reports we file with the Securities and Exchange Commission. We do not intend, and undertake no obligation, to update any forward-looking statements, whether as a result of new information, future events or otherwise.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
AeroVironment (AVAV) Reports Earnings Tomorrow: What To Expect
Aerospace and defense company AeroVironment (NASDAQ:AVAV) will be announcing earnings results this Tuesday afternoon. Here's what investors should know. AeroVironment missed analysts' revenue expectations by 10.9% last quarter, reporting revenues of $167.6 million, down 10.2% year on year. It was a disappointing quarter for the company, with full-year revenue guidance missing analysts' expectations significantly and full-year EBITDA guidance missing analysts' expectations significantly. Is AeroVironment a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting AeroVironment's revenue to grow 23.7% year on year to $243.7 million, improving from the 5.9% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.41 per share. Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. AeroVironment has only missed Wall Street's revenue estimates once over the last two years, exceeding top-line expectations by 5.6% on average. Looking at AeroVironment's peers in the aerospace and defense segment, some have already reported their Q1 results, giving us a hint as to what we can expect. HEICO delivered year-on-year revenue growth of 14.9%, beating analysts' expectations by 3.5%, and Redwire reported a revenue decline of 30.1%, falling short of estimates by 16.5%. HEICO traded up 7.4% following the results while Redwire's stock price was unchanged. Read our full analysis of HEICO's results here and Redwire's results here. Investors in the aerospace and defense segment have had steady hands going into earnings, with share prices flat over the last month. AeroVironment is up 7.2% during the same time and is heading into earnings with an average analyst price target of $195.38 (compared to the current share price of $190.94). Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.
Business Wire
8 hours ago
- Business Wire
Exelixis Announces Zanzalintinib in Combination with an Immune Checkpoint Inhibitor Improved Overall Survival in STELLAR-303 Phase 3 Pivotal Trial in Patients with Metastatic Colorectal Cancer
BUSINESS WIRE)-- Exelixis, Inc. (Nasdaq: EXEL) today announced positive topline results from the STELLAR-303 phase 3 pivotal trial in which zanzalintinib in combination with atezolizumab (Tecentriq ®) demonstrated a statistically significant improvement in overall survival (OS) versus regorafenib in the intent-to-treat (ITT) population of patients with previously treated non-microsatellite instability (MSI)-high metastatic colorectal cancer (CRC). These topline findings are from the final analysis conducted by the Independent Data Monitoring Committee of one of the dual primary endpoints of the STELLAR-303 phase 3 trial. The trial will proceed to the planned final analysis for the other dual primary endpoint of OS in patients without liver metastases (non-liver metastases, NLM). The safety profiles of zanzalintinib in combination with atezolizumab and of regorafenib were generally consistent with what has been previously observed, and no new safety signals were identified. The ITT population consisted of all randomized patients, regardless of the presence of liver metastases. The NLM subgroup consisted of patients who did not have active liver metastases at baseline as determined by investigator assessment. 'The STELLAR-303 results, which showed a survival benefit with the combination of zanzalintinib and atezolizumab versus regorafenib across all randomized patients with previously treated metastatic colorectal cancer, marks an important first milestone for our zanzalintinib pivotal development program,' said Amy Peterson, M.D., Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer, Exelixis. 'We look forward to discussing the findings with regulatory authorities and presenting the detailed results at an upcoming medical conference.' Secondary endpoints of STELLAR-303 include progression-free survival, objective response rate and duration of response in the ITT population and in the NLM subgroup of patients. Exelixis plans to submit detailed results of STELLAR-303 for presentation at an upcoming medical conference. About STELLAR-303 STELLAR-303 (NCT05425940) is a global, multicenter, randomized, phase 3, open-label study that randomized 901 patients 1:1 to either zanzalintinib (100 mg) in combination with atezolizumab or regorafenib. The study includes patients with previously treated non-MSI-high metastatic CRC. The dual primary endpoints of the study are OS in the ITT population and in the NLM subgroup of patients. Presence of liver metastases at baseline for all enrolled patients was determined by investigator assessment. Secondary endpoints include progression-free survival, objective response rate and duration of response in the ITT population and in the NLM subgroup of patients. More information about the trial is available at About Zanzalintinib Zanzalintinib is a third-generation oral tyrosine kinase inhibitor that inhibits the activity of receptor tyrosine kinases implicated in cancer growth and spread, including VEGF receptors, MET, AXL and MER. These receptor tyrosine kinases are involved in both normal cellular function and in pathologic processes such as oncogenesis, metastasis, tumor angiogenesis and resistance to multiple therapies, including immune checkpoint inhibitors. With zanzalintinib, Exelixis sought to build upon its extensive experience with the target profile of cabozantinib, the company's flagship medicine, while improving key characteristics, including pharmacokinetic half-life. Zanzalintinib is currently being developed for the treatment of advanced solid tumors, including colorectal cancer, kidney cancer, head and neck cancer and neuroendocrine tumors. Zanzalintinib is an investigational agent that is not approved for any use and is the subject of ongoing clinical trials. About CRC CRC is the third most common cancer and the second leading cause of cancer-related deaths in the U.S. 1 Approximately 154,000 new cases will be diagnosed in the U.S. with around 53,000 expected deaths from the disease in 2025. 1 CRC is most frequently diagnosed among people aged 65-74 and is more common in men and in people of non-Hispanic American Indian/Alaska Native descent. 2 Nearly a quarter of CRC cases are diagnosed at the metastatic stage, at which point the five-year survival rate is just 16.2%. 2 The liver is the most common site for CRC metastasis. Liver metastases significantly impact survival, with a median five-year survival rate of less than 14% when treated with palliative chemotherapy. 3 About Exelixis Exelixis is a globally ambitious oncology company innovating next-generation medicines and regimens at the forefront of cancer care. Powered by drug discovery and development excellence, we are rapidly evolving our product portfolio to target an expanding range of tumor types and indications with our clinically differentiated pipeline of small molecules, antibody-drug conjugates and other biotherapeutics. This comprehensive approach harnesses decades of robust investment in our science and partnerships to advance our investigational programs and extend the impact of our flagship commercial product, CABOMETYX ® (cabozantinib). Exelixis is driven by a bold scientific pursuit to create transformational treatments that give more patients hope for the future. For information about the company and its mission to help cancer patients recover stronger and live longer, visit follow @ExelixisInc on X (Twitter), like Exelixis, Inc. on Facebook and follow Exelixis on LinkedIn. Forward-Looking Statements This press release contains forward-looking statements, including, without limitation, statements related to: the therapeutic potential of the combination of zanzalintinib in combination with atezolizumab to improve overall survival in patients with metastatic CRC; Exelixis' plans to discuss the trial data from STELLAR-303 with regulatory authorities and to present detailed findings at an upcoming medical conference; and Exelixis' scientific pursuit to create transformational treatments that give more patients hope for the future. Any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements and are based upon Exelixis' current plans, assumptions, beliefs, expectations, estimates and projections. Forward-looking statements involve risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in the forward-looking statements as a result of these risks and uncertainties, which include, without limitation: the availability of data at the referenced times; complexities and the unpredictability of the regulatory review and approval processes in the U.S. and elsewhere; Exelixis' continuing compliance with applicable legal and regulatory requirements; unexpected concerns that may arise as a result of the occurrence of adverse safety events or additional data analyses of clinical trials evaluating zanzalintinib; Exelixis' dependence on third-party vendors for the development, manufacture and supply of zanzalintinib; Exelixis' ability to protect its intellectual property rights; market competition; changes in economic and business conditions; and other factors affecting Exelixis and its development programs detailed from time to time under the caption 'Risk Factors' in Exelixis' most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, and in Exelixis' future filings with the Securities and Exchange Commission. All forward-looking statements in this press release are based on information available to Exelixis as of the date of this press release, and Exelixis undertakes no obligation to update or revise any forward-looking statements contained herein, except as required by law. Exelixis, the Exelixis logo and CABOMETYX are registered U.S. trademarks of Exelixis. TECENTRIQ is a registered U.S. trademark of Genentech, a member of the Roche Group. ___________________________ 1 Key Statistics for Colorectal Cancer. ACS website. Available at: Accessed June 2025. 2 Cancer Stat Facts: Colorectal Cancer. SEER website. Available at: Accessed June 2025. 3 Ros J, Salva F, Dopazo C, et al. Liver transplantation in metastatic colorectal cancer: are we ready for it? Br J Cancer. May 2023;128(10):1797-1806.
Chicago Tribune
a day ago
- Chicago Tribune
Sunken Bayesian superyacht lifted from waters off Sicily as salvage operation completed
PORTICELLO, Italy — A British-flagged luxury superyacht that sank off Sicily last year, killing U.K. tech magnate Mike Lynch and six others, was lifted from the water Saturday as salvage recovery crews completed the complex operation to bring it ashore for further investigation. The white top and blue hull of the 56-meter (184-foot) Bayesian, covered with algae and mud, was visibly clear of the sea in a holding area of a yellow floating crane barge off the Sicilian port of Porticello. 'The hull of the superyacht Bayesian has today been successfully and safely recovered from the sea off the coast of northern Sicily,' said TMC Maritime, the company conducting the recovery. 'This follows a delicate lifting procedure that began early today.' TMC added that the hull will continue to be held 'in an elevated position to allow expert salvage personnel to complete checks and preparations' ahead of its transportation into the Sicilian port of Termini Imerese on Sunday. The floating crane platform will move the Bayesian to the port, where a special steel cradle is waiting for it. The vessel will be then made available for investigators to help determine the cause of the sinking. The Bayesian sank Aug. 19 off Porticello, near Palermo, during a violent storm as Lynch was treating friends to a cruise to celebrate his acquittal two months earlier in the U.S. on fraud charges. Lynch, his daughter and five others died. Fifteen people survived, including the captain and all crew members except the chef. Italian authorities are conducting a full criminal investigation. The vessel has been slowly raised from the seabed, 50 meters (165-feet) down, over the past three days to allow the steel lifting straps, slings and harnesses to be secured under the keel. Eight steel lifting straps were used to put the hull upright and to form part of a steel wire lifting system that began raising the vessel out of the water Saturday. As the superyacht was raised, seawater was pumped out of the hull. The Bayesian is missing its 72-meter (236-foot) mast, which was cut off and left on the seabed for future removal. The mast had to be detached to allow the hull to be brought to a nearly upright position that would allow the craft to be raised. British investigators said in an interim report issued last month that the yacht was knocked over by 'extreme wind' and couldn't recover. The report said the crew of the Bayesian had chosen the site where it sank as shelter from forecast thunderstorms. Wind speeds exceeded 70 knots (81 mph) at the time of the sinking and 'violently' knocked the vessel over to a 90-degree angle in under 15 seconds. Lynch, who sold Autonomy, a software maker he founded in 1996, to Hewlett-Packard for $11 billion in 2011, had been acquitted of fraud charges in June 2024 by a federal court jury in San Francisco.
